Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2168-4804
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021 ; volume:56 ; number:5 ; day:28 ; month:7 ; year:2022 ; pages:698-703 ; date:9.2022
Therapeutic innovation & regulatory science ; 56, Heft 5 (28.7.2022), 698-703, 9.2022
- Urheber
-
Beakes-Read, Ginny
Neisser, Madison
Frey, Patrick
Guarducci, Mara
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s43441-022-00430-z
- URN
-
urn:nbn:de:101:1-2022102122554352700166
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Beakes-Read, Ginny
- Neisser, Madison
- Frey, Patrick
- Guarducci, Mara
- SpringerLink (Online service)
Ähnliche Objekte (12)
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA efficiency for approval process of COVID-19 therapeutics
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
December: December
December: December
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
![[2 December - 30 December]](https://iiif.deutsche-digitale-bibliothek.de/image/2/96209dd6-8bd1-4148-b63b-5b32fb6cf17e/full/!306,450/0/default.jpg)
[2 December - 30 December]
10. December-21. December
21. December - 31. December
11. December - 20. December
1. December - 10. December
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA efficiency for approval process of COVID-19 therapeutics
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
December: December
December: December
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
[2 December - 30 December]
10. December-21. December
21. December - 31. December
11. December - 20. December
1. December - 10. December
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA efficiency for approval process of COVID-19 therapeutics
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
December: December
December: December
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
[2 December - 30 December]
10. December-21. December
21. December - 31. December
11. December - 20. December